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RpoS-independent evolution 
reveals the importance of 
attenuated cAMP/CRP regulation 
in high hydrostatic pressure 
resistance acquisition in E. coli
Elisa Gayán, Alexander Cambré, Chris W. Michiels  & Abram Aertsen
High hydrostatic pressure (HHP) processing is an attractive non-thermal alternative to food 
pasteurization. Nevertheless, the large inter- and intra-species variations in HHP resistance among 
foodborne pathogens and the ease by which they can acquire extreme resistance are an issue of 
increasing concern. Since RpoS activity has been considered as a central determinant in the HHP 
resistance of E. coli and its pathovars, this study probed for the potential of an E. coli MG1655 ΔrpoS 
mutant to acquire HHP resistance by directed evolution. Despite the higher initial HHP sensitivity of 
the ΔrpoS mutant compared to the wild-type strain, evolved lineages of the former readily managed 
to restore or even succeed wild-type levels of resistance. A number of these ΔrpoS derivatives were 
affected in cAMP/CRP regulation, and this could be causally related to their HHP resistance. Subsequent 
inspection revealed that some of previously isolated HHP-resistant mutants derived from the wild-type 
strain also incurred a causal decrease in cAMP/CRP regulation. cAMP/CRP attenuated HHP-resistant 
mutants also exhibited higher resistance to fosfomycin, a preferred treatment for STEC infections. 
As such, this study reveals attenuation of cAMP/CRP regulation as a relevant and RpoS-independent 
evolutionary route towards HHP resistance in E. coli that coincides with fosfomycin resistance.
High hydrostatic pressure (HHP) treatment is a promising alternative to conventional thermal pasteurization 
of foods as it is able to improve the microbial stability and safety of foods without compromising its fresh-like 
attributes. However, while commercial HHP treatment ranging from 400 to 600 MPa can achieve a significant 
level of reduction of most vegetative spoilage and pathogenic foodborne bacteria1, an important concern remains 
the extensive HHP resistance displayed by some bacterial strains2–4. In particular, a substantial proportion of 
Shiga-toxigenic Escherichia coli (STEC) isolates appears to be resistant to exposures of 600 MPa3, 5. Furthermore, 
extreme HHP resistance is a trait that can reproducibly be genetically acquired by E. coli when iteratively exposed 
to HHP shocks4, 6.
The mechanism underlying bacterial inactivation by HHP treatment is still not well understood; however, 
some cellular targets and stress responses involved in pressure survival have been identified7–9. In particular, the 
general stress response governed by the RpoS sigma factor strongly contributes to HHP resistance in E. coli, which 
in part could be traced back to the RpoS mediated upregulation of cyclopropane fatty acid synthase, outer mem-
brane lipoproteins and trehalose-6-phosphate synthase10, 11. Indeed, stationary phase induction of this general 
stress response accounts for the increased HHP resistance of stationary over exponential phase cells10. Moreover, 
also the large variability in pressure resistance among natural STEC isolates has been related to polymorphisms in 
their rpoS allele and the corresponding variations in cellular RpoS activity5, 11.
These polymorphisms are thought to reflect the evolutionary adaptation of different E. coli populations to their 
particular ecological niches12, 13. In fact, strains with attenuated RpoS activity tend to display an improved use of 
secondary carbon sources like succinate, fumarate and acetate at the expense of self-preservation under stress12, 14, 
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while strains with a high basal RpoS activity display increased stress resistance at the expense of nutritional com-
petence15. Furthermore, given the extensive regulatory network surrounding RpoS activity16, modulatory muta-
tions affecting this activity are likely to occur at a relative high frequency, enabling lineages to balance between 
self-preservation (with high RpoS activity) and nutritional competence (with low RpoS activity) (also referred 
to as the SPANC balance)17. As a result, modulation of the RpoS response seems to be an important evolutionary 
strategy in E. coli to improve nutritional competence on the one hand or stress tolerance and cross-resistance on 
the other.
The latter also became clear when exposure of E. coli O157:H7 (ATCC 43888) to a limited number of pro-
gressively intensifying HHP shocks rapidly selected for mutants that were cross-resistant to mild pressure (id est 
300 MPa) and heat, and that showed signs of increased RpoS activity15. A random transposon knock-out screen 
subsequently confirmed the role of RpoS activity in HHP resistance of ATCC 43888, as a disruption of the rssB 
gene (encoding an anti-RpoS factor that binds to RpoS and quenches its activity16) yielded a similar HHP and 
heat cross-resistance18. Interestingly, the same transposon screen also revealed that disruption of either the cyaA 
(encoding the adenylate cyclase or cAMP synthetase) or crp (encoding the cAMP Receptor Protein) gene could 
confer HHP resistance as well. Even though lack of cAMP/CRP regulation has been described to increase rpoS 
expression, it remains unclear whether or not the underlying mechanism is dependent on RpoS18, 19. Nevertheless, 
given the growth defect imposed by cyaA or crp mutations20, we anticipated that mutants spontaneously compro-
mised in these loci could not readily enrich in populations evolving towards HHP resistance18.
Given the central and perhaps also dominant role of the RpoS global regulator in HHP resistance and resist-
ance development, this study aimed to investigate the remaining potential of E. coli to develop HHP resistance 
in the absence of this sigma factor, in order to elucidate potential alternative evolutionary pathways that are truly 
independent of RpoS upregulation.
Results
Evolution of E. coli MG1655 ΔrpoS towards HHP resistance. To examine the intrinsic ability of E. 
coli MG1655 lacking RpoS to develop HHP resistance, an MG1655 ΔrpoS derivative was constructed and five 
independent cultures of this mutant strain were subjected to successive cycles of increasingly severe HHP shock 
(starting at 200 MPa, with 30 MPa increments each cycle up to 470 MPa) with intermittent outgrowth of survivors. 
Figure 1 illustrates the evolution of the HHP resistance of the ΔrpoS lineages during the selection regimen in 
comparison to the inactivation of the original ΔrpoS and WT parental strains. As anticipated, deprivation of the 
rpoS gene sensitized the ΔrpoS strain to HHP treatment, resulting in a circa 1,000-fold higher (P ≤ 0.05) inacti-
vation at 470 MPa compared to the WT strain.
Despite this parental HHP hypersensitivity, however, each of the five evolving MG1655 ΔrpoS lineages man-
aged to develop piezotolerance, with the single clones subsequently isolated from each of the five lineages (des-
ignated MT1 to MT5) being on average 2.8 log10 cycles more resistant than the parental ∆rpoS background at 
470 MPa (data not shown). Further phenotypic analysis of these five clones revealed varying levels of HHP resist-
ance, with three clones even displaying a HHP resistance equal (P > 0.05; i.e. MT3) or significantly (P ≤ 0.05) 
higher (i.e. MT1 and MT4) than the MG1655 WT (i.e. rpoS proficient) parent at 500 MPa despite lacking RpoS 
activity (Fig. 2A). Interestingly, HHP resistance in the evolved ∆rpoS strains did not necessarily coincide with 
heat resistance as MT1 even became significantly (P ≤ 0.05) more sensitive to a 57 °C shock than its ∆rpoS parent 
(Fig. 2B).
Importantly, when three independent lineages of the ancestral ∆rpoS strain were subcultured for ca. 66 
generations without imposing any stress, their HHP inactivation (at 470 MPa) actually significantly (P ≤ 0.05) 
increased by 0.7 log10 cycle on average (data not shown), indicating that serial passaging itself did not select for 
pressure resistance.
Figure 1. Evolution of the HHP resistance of five independent axenic cultures of an E. coli MG1655 ∆rpoS 
strain iteratively exposed to progressively intensifying HHP shocks (15 min) with intermittent resuscitation and 
growth of survivors. The line graphs show the inactivation (i.e. logarithmic reduction factor, log10 [N0/N]) of the 
five evolving lineages (●, lineage 1; ■, lineage 2; ▼, lineage 3; ▲, lineage 4; ×, lineage 5) during the stepwise 
selection regime with 30 MPa increments, while the gray bars represent the resistance of the unevolved MG1655 
∆rpoS parental strain (i.e. without previous HHP exposure). To illustrate the effect of RpoS activity on HHP 
resistance, the inactivation of E. coli MG1655 WT (i.e. RpoS proficient) strain is included as well (white bars). 
The dotted line represents the quantification limit (1,000 CFU/ml). An asterisk indicates statistically significant 
differences (P ≤ 0.05) between the inactivation of the parental ∆rpoS and WT strain at indicated pressures.
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Compromised CRP activity can explain the HHP resistance phenotype of some evolved E. 
coli MG1655 ΔrpoS mutants. Since a random transposon knock-out screen performed earlier in E. coli 
O157:H7 (strain ATCC 43888) had revealed that disruption of cAMP/CRP homeostasis could confer HHP resist-
ance18, we examined whether cAMP/CRP regulation was compromised in the evolved ΔrpoS mutants. As lactose 
metabolism in E. coli requires a functional cAMP/CRP complex, we first examined the evolved ΔrpoS mutants 
for their lactose fermentation phenotype on MacConkey agar (Table 1 and Supplementary Fig. S1). Interestingly, 
the size of the pink halo of the most piezotolerant ΔrpoS mutants (i.e. MT1, MT3 and MT4) was visibly reduced 
in comparison to the ΔrpoS parent. Moreover, this phenotype persisted regardless of the addition of cAMP to the 
MacConkey medium. Sequencing subsequently revealed that MT1 incurred an IS2 insertion of ca. 1.3 kb length 
in the crp promoter region, while the crp gene of MT4 incurred a point mutation resulting in an V184M amino 
acid substitution in the DNA-binding domain of CRP21 (Table 1). Most of the randomly picked clones from 
lineage 1 and 4 (where MT1 and MT4 stemmed from, respectively) displayed a similarly attenuated MacConkey 
phenotype, indicating that these variants constituted the majority of the evolved populations.
Despite the fact that MT3 clearly displayed a reduced pink halo on MacConkey agar, it did not show growth 
defects on M9 lactose (Table 1) or significantly (P > 0.05) reduced β-galactosidase activity compared to its ∆rpoS 
parent as did MT1 and MT4 (Supplementary Fig. S2). Furthermore, its crp and cyaA loci appeared to be intact, 
and therefore the altered MacConkey phenotype of this mutant is likely not causally linked to cAMP/CRP 
downregulation. In MT2 and MT5, growth on MacConckey agar and M9 lactose, β-galactosidase activity and 
the sequences of crp and cyaA loci were unaltered compared to the ΔrpoS parent (Table 1 and Supplementary 
Fig. S2).
In order to confirm that a compromised CRP functionality is indeed causally linked to the HHP resistance 
phenotype of MT1 and MT4, the evolved ΔrpoS mutants were equipped with a plasmid-borne copy of the crp 
gene (using pACYC184-crp18) and exposed to pressure (500 MPa). Please note that the HHP resistance of the 
∆rpoS parent and some of its derivatives (i.e. MT2 and MT5) significantly (P ≤ 0.05) decreased by ca. 1.1 log10 
cycles in the presence of the pACYC184 control vector (Figs. 2A and 3), likely due to energy draining that can 
constitute a burden for the cells22. To avoid the interference of this artefact in the interpretation of the com-
plementation assays, the effect of gene complementation on HHP survival was evaluated in comparison to the 
strains equipped with the control plasmid. As shown in Fig. 3, provision of CRP significantly (P ≤ 0.05) decreased 
the HHP survival of MT1 and MT4 by 4.2 log10 cycles on average. Moreover, in agreement with the lack of 
cAMP complementation already observed in the lactose fermentation assay (Table 1), complementation with a 
Figure 2. Logarithmic reduction factor of E. coli MG1655 WT and indicated mutants by a HHP treatment at 
500 MPa (a) or heat treatment at 57.0 °C (b) for 15 min. The dotted line represents the quantification limit (1,000 
CFU/ml). Letters indicate statistically significant differences (P ≤ 0.05) among the inactivation of all strains.
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plasmid-borne cyaA gene (using pACYC184-cyaA18) did not significantly (P > 0.05) attenuate the HHP resist-
ance of MT1 and MT4. The inactivation of the ∆rpoS parent also decreased significantly (P ≤ 0.05) but to a lower 
extent (ca. 0.8 log10 cycle) when equipped with pACYC184-crp and pACYC184-cyaA at 400 MPa (Supplementary 
Fig. 3S). In contrast, neither of the complementation plasmids significantly (P > 0.05) affected the HHP resistance 
of MT2 and MT5. In the case of MT3, which displayed altered MacConkey phenotype without compromising 
lactose fermentation and harboring intact crp and cyaA alleles, complementation with both pACYC184-crp or 
pACYC184-cyaA appeared to significantly (P ≤ 0.05) attenuate HHP resistance by 1.7 log10 cycles on average, 
indicating that this mutant might for some other reason be more susceptible to overdosing CRP and CyaA.
Compromised cAMP/CRP regulation also contributes to the phenotype of extremely HHP 
resistant E. coli MG1655 mutants. Spurred by the impact and evolvability of cAMP/CRP regulation 
in HHP resistance development of the ΔrpoS parent, a number of previously documented mutants that were 
evolved starting from a wild-type (i.e. RpoS proficient) MG1655 background to withstand exposure to 800 MPa 
and higher4, 6, 23 were evaluated on MacConkey agar, M9 lactose and β-galactosidase activity for their capacity to 
utilize lactose (Table 1 and Supplementary Fig. S2).
Strain
Size of the pink halo in 
MacConkey agara Growth on M9b
crp/cyaA mutation−cAMP +cAMP Glucose Lactose
WT ++++ ++++ ++++ ++++
Δcrp − − +++ −
ΔcyaA − ++++ +++ −
ΔrpoS ++++ ++++ ++++ ++++
ΔrpoS Δcrp − − +++ −
ΔrpoS ΔcyaA − ++++ +++ −
MT1 +++ +++ ++++ ++ crp: insertion of IS2 in the promoter region
MT2 ++++ ++++ ++++ ++++
MT3 ++ ++ ++++ ++++
MT4 − − +++ + crp: G550A
MT5 ++++ ++++ ++++ ++++
LMM1010 + ++++ ++++ ++ cyaA: insertion of A at position 990
LMM1020 ++ ++ ++++ +++ crp: G248C, T446A
LMM1030 ++++ ++++ ++++ ++++
DVL20 ++++ ++++ ++++ ++++
DVL1 + ++++ ++++ ++ cyaA: insertion of TATAG at position 1,923
Table 1. Phenotypic characterization of E. coli MG1655 WT and its indicated mutants on MacConkey lactose 
agar with or without 5 mM of cAMP added, and on M9 glucose or lactose agar. The corresponding mutations 
found in the crp or cyaA sequence (if any) are indicated. aThe size of the pink halo formed by 20 µl of stationary 
phase cultures diluted 1/100 in 0.85% KCl after overnight incubation was scored from − (no halo) to ++++ 
with respect to the Δcrp and ΔcyaA mutants and the WT and ∆rpoS parent, respectively (Supplementary 
Fig. S1). bThe growth of 5 µl of stationary phase cultures diluted 1/100 in M9 salts after 48 h of incubation was 
scored from − (no growth) to ++++ with respect to the Δcrp and ΔcyaA mutants and the WT and ∆rpoS 
parent, respectively.
Figure 3. Logarithmic reduction factor of E. coli MG1655 WT, ΔrpoS and ΔrpoS evolved mutants equipped 
with pACYC184 (control vector; grey bars), pACYC184-crp (black bars) or pACYC184-cyaA (hatched bars) by 
a HHP treatment at 500 MPa for 15 min. The dotted line represents the quantification limit (1,000 CFU/ml). An 
asterisk indicates statistically significant differences (P ≤ 0.05) between the inactivation of each strain equipped 
with pACYC184-crp or pACYC184-cyaA and the control vector.
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As such, it appeared that strain LMM1010, LMM1020 and DVL1 indeed displayed a clearly compromised 
lactose fermentation, and that the addition of cAMP to the MacConkey medium could completely alleviate this 
phenotype in LMM1010 and DVL1. Correspondingly, LMM1010 and DVL1 were subsequently found to harbor 
frameshift mutations in their cyaA gene, while LMM1020 incurred two point mutations in its crp gene (Table 1). 
The latter resulted in two amino acid substitutions, one in the cAMP binding site (R83P) and another in the 
DNA binding domain (L149Q)21. In agreement with the observed mutations, the HHP resistance of LMM1010 
and DVL1 became significantly (P ≤ 0.05) attenuated by 3.1 log10 reductions on average when equipped with 
pACYC184-cyaA but not with pACYC184-crp (Fig. 4). The HHP resistance of LMM1020 was significantly 
(P ≤ 0.05) reduced by 3.0 log10 cycles in the presence of pACYC184-crp and to a lesser extent (ca. 1 log10 cycle) by 
pACYC184-cyaA.
Strain LMM1030 and DVL20 did not suffer compromised lactose fermentation nor mutations in their crp and 
cyaA loci (Table 1 and Supplementary Fig. S2). The HHP resistance of DVL20 suffered a marginal but significant 
(P ≤ 0.05) reduction of 1.2 log10 cycles from the presence of pACYC184-crp. Similarly, the survival of the WT 
strain to 600 MPa also significantly (P ≤ 0.05) decreased by 0.9 log10 cycle when complemented with both plas-
mids (Supplementary Fig. S3). Interestingly, both complementation vectors significantly (P ≤ 0.05) attenuated the 
HHP resistance of LMM1030 by 2.3 log10 reductions on average, suggesting again that this mutant is sensitized to 
cAMP/CRP upregulation by an alternative mechanism.
Synthetic reconstruction confirms lack of cAMP/CRP regulation as cause of HHP resistance in 
E. coli MG1655. In order to study the impact of cAMP/CRP regulation on HHP resistance in a more defined 
genetic background (i.e. not exposed to directed evolution), the crp or cyaA gene was synthetically deleted in the 
WT or ΔrpoS parent, after which HHP resistance of the resulting strains was examined. This unambiguously 
established that complete loss of either of the components giving rise to the cAMP/CRP complex could signifi-
cantly (P ≤ 0.05) improve the HHP resistance in both a ΔrpoS (ca. 2,000-fold at 500 MPa [Fig. 2A]) and WT (ca. 
100-fold at 500 MPa [Fig. 2A] and 800 MPa [Fig. 5]) background.
Furthermore, when the crp allele of MT4 (i.e. the most HHP resistant mutant obtained in the ∆rpoS par-
ent) was chromosomally reconstructed in its parental strain (leading to ΔrpoS crpMT4), the HHP resistance of 
∆rpoS strain increased ca. 600-fold (P ≤ 0.05) at 500 MPa (Fig. 6). In the same vein, replacing the chromosomal 
crpMT4 allele in MT4 with the fully functional wild-type crp allele (leading to MT4 crpWT) significantly (P ≤ 0.05) 
attenuated the HHP resistance of MT4 by 2.6 log10 cycles, while similarly replacing the crpMT4 allele with the 
non-functional Δcrp allele (leading to MT4 Δcrp) did not affect (P > 0.05) its HHP resistance (Fig. 6). These 
Figure 4. Logarithmic reduction factor of E. coli MG1655 WT and its evolved mutants equipped with 
pACYC184 (control vector; grey bars), pACYC184-crp (black bars) or pACYC184-cyaA (hatched bars) by a 
HHP treatment at 800 MPa for 15 min. The dotted line represents the quantification limit (1,000 CFU/ml). An 
asterisk indicates statistically significant differences (P ≤ 0.05) between the inactivation of each strain equipped 
with pACYC184-crp or pACYC184-cyaA and the control vector.
Figure 5. Logarithmic reduction factor of E. coli MG1655 WT and indicated mutants by a HHP treatment 
at 800 MPa for 15 min. The dotted line represents the quantification limit (1, 000 CFU/ml). Letters indicate 
statistically significant differences (P ≤ 0.05) among the inactivation of all strains.
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observations further underscore the central role of crpMT4 as a loss-of-function allele in the HHP resistance of 
MT4.
It should nevertheless be noted that the HHP resistance of the spontaneously evolved cAMP/CRP compro-
mised mutants (i.e. obtained after directed evolution of the ΔrpoS and WT parents) often still remained higher 
than the synthetically reconstructed strains, suggesting secondary determinants to contribute to HHP resistance 
as well. In particular, while the survival of MT1 to 500 MPa matched (P > 0.05) the inactivation of the ΔrpoS 
background lacking crp or cyaA locus, the HHP resistance of MT4 was ca. 1 log10 cycle significantly (P ≤ 0.05) 
higher than that of ΔrpoS Δcrp and ΔrpoS ΔcyaA strains (Fig. 2A). Likewise, the synthetically converted MT4 
crpWT strain clearly suffered attenuated HHP resistance compared to MT4, but still remained ca. 30-fold more 
resistant (P ≤ 0.05) than the ∆rpoS parent (Fig. 6). Finally, the survival of LMM1010, LMM1020 and DVL1 to 
extreme HHP treatment (i.e. 800 MPa) was also significantly (P ≤ 0.05) higher (from 0.9 to 1.9 log10 cycles) than 
that of the WT parent in the absence of crp or cyaA (Fig. 5).
HHP resistant E. coli MG1655 mutants compromised in cAMP/CRP regulation display 
cross-resistance to fosfomycin but not to heat. In contrast to its effect on HHP resistance, deletion 
of crp or cyaA did not significantly (P > 0.05) improve heat resistance in an ΔrpoS or WT MG1655 background 
(Fig. 2B). This specific impact was quite different from an RpoS upregulated mutant such as MG1655 ∆rssB 
(which lacks the anti-RpoS factor that would otherwise quench RpoS activity16, 18) in which the stimulated general 
stress response yielded cross-resistance to both HHP and heat (Fig. 2). Since RpoS activity and lack of cAMP/
CRP regulation seem to contribute to HHP resistance independently from each other, we examined whether the 
combination of RpoS upregulation (by deleting the rssB gene) and cAMP/CRP downregulation (by also deleting 
either the crp or cyaA gene) could further improve HHP resistance. However, it appeared that deletion of rssB did 
not significantly (P > 0.05) change the HHP resistance of a Δcrp or ΔcyaA mutant at 800 MPa (Fig. 5), being all 
equally ca. 100-fold more resistant (P ≤ 0.05) than the WT strain.
As it was previously found that mutants with decreased cAMP/CRP activity display an increased resist-
ance to fosfomycin24, 25, which has been regarded as one of the preferred antibiotic treatment options for STEC 
infections26, 27, the spontaneous HHP resistant mutants raised in this study were examined for their fosfomycin 
resistance. Table 2 indeed shows that the fosfomycin MIC value for the mutants directly affected in cAMP/CRP 
regulation (MT1, MT4, LMM1010, LMM1020 and DVL1; with ∆crp and ∆cyaA strains as a control) increased 
from 2-fold (LMM1020 and DVL1) to 16-fold (MT4) compared to their parental strain, while mutants that did 
not incur cyaA or crp mutations (MT2, MT3, MT5, LMM1030 and DVL20) maintained the same fosfomycin 
resistance as their parental strain.
Discussion
RpoS activity has previously been established as a central determinant in stationary phase HHP resistance in E. 
coli, and mutations upregulating the activity of this sigma factor therefore highlight one evolutionary strategy 
towards HHP resistance development11, 15. Surprisingly, however, an E. coli genetic background deprived of the 
RpoS protein and therefore hypersensitive to HHP shock readily managed to acquire wild-type (or even higher) 
levels of HHP resistance upon recurrent exposure to HHP shock. Further analysis subsequently revealed that 
compromised cAMP/CRP regulation was causally involved in HHP resistance development of two (i.e. MT1 
and MT4) of the five independently evolved ΔrpoS mutants. Furthermore, mutations compromising cAMP/
CRP regulation were also discovered to causally contribute to the phenotype of extremely HHP resistant (and 
RpoS proficient) E. coli mutants that were evolved in earlier studies6, 23. To the best of our knowledge, this study 
Figure 6. Logarithmic reduction factor of E. coli MG1655 ∆rpoS equipped with a crp deletion (∆rpoS ∆crp) 
or the crp allele from MT4 (∆rpoS crpMT4), and MT4 equipped with a crp deletion (MT4 ∆crp) or the wild-type 
crp allele (MT4 crpWT) by a HHP treatment at 500 MPa for 15 min. The dotted line represents the quantification 
limit (1,000 CFU/ml). Letters indicate statistically significant differences (P ≤ 0.05) among the inactivation of all 
strains.
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is therefore the first to identify and phenotypically validate cyaA and crp mutations as causal HHP resistance 
conferring mutations arising in spontaneously evolved mutants of E. coli.
In Listeria monocytogenes (strains LO28 and ScottA), spontaneous mutations leading to HHP resistance have 
been documented earlier and found to compromise the ctsR gene, which encodes the class III heat shock repres-
sor28–30. Disruption of the ctsR gene can lead to a defect in the repression of clpC family chaperones which results 
in transcription of these stress response genes and consequently in increased cross-resistance to HHP, heat, acidity 
and H2O22, 28. In contrast, cAMP/CRP regulation has a more pleiotropic and metabolically oriented impact on E. 
coli physiology, and a large number of genes are responsive to cAMP/CRP activation or repression31. Intriguingly, 
mutations attenuating CyaA or CRP functionality have previously been found to affect osmotic32, acid19, 33, heat34 
and oxidative19, 35, 36 stress resistance of E. coli, although the latter phenotypes might indirectly stem from upreg-
ulation of the rpoS gene which is repressed by cAMP/CRP19, 36. Moreover, while this report clearly underscores 
compromised cAMP/CRP activity to support HHP resistance in an RpoS independent manner, both transcrip-
tional regulators oppositely affect a largely overlapping set of downstream genes37, 38. As such, it could well be that 
(some of) the functions required to withstand or address HHP stress in the cell are independently but similarly 
directed by either the upregulation of RpoS or the downregulation of cAMP/CRP. However, the phenotypic con-
stitution of mutants with increased RpoS activity or decreased cAMP/CRP activity is bound to differ, since RpoS 
upregulation (by deleting ΔrssB) supports both HHP and heat resistance while cAMP/CRP downregulation (by 
deleting cyaA or crp) only seems to support HHP resistance in E. coli MG1655.
Importantly, we also demonstrated that HHP resistant clones with mutations in crp or cyaA displayed 2- to 
16-fold higher resistance to fosfomycin than the parental strains. Fosfomycin is an antibiotic that targets the 
UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) that is involved in the first step of peptidogly-
can synthesis39, and the observed resistance is likely due to decreased expression of the glycerol-3-phosphate 
transporter (GlpT) and the hexose phosphate transporter (UhpT) in the absence of cAMP/CRP complex24, 25. 
These transporters are responsible for the uptake of fosfomycin in the cell due to its similar structure to 
phosphorylated sugars39. Besides being an alternative drug for urinary and systemic infections caused by 
multidrug-resistant Enterobacteriaceae40, fosfomycin is actually proposed as one of the antibiotic therapies of 
choice for STEC infections26, 27. Indeed, in contrast to DNA damaging antibiotics such as fluoroquinolones and 
trimethoprim-sulfamethoxazole that tend to activate the lytic cycle of the Shigatoxin (Stx) encoding prophages 
in STEC and thereby improve the production and release of Stx, fosfomycin has no effect on Stx expression 
and might therefore reduce the risk of haemolytic uremic syndrome development caused by Stx41–43. The poten-
tial of HHP treatment to select for cAMP/CRP compromised HHP resistant E. coli mutants with a concomi-
tantly decreased susceptibility to fosfomycin can therefore pose a concern for food safety that should be further 
investigated.
Finally, it should be noted that some ∆rpoS mutants developed HHP resistance without apparent cyaA or crp 
mutations or lactose metabolism defects (i.e. MT2, MT3 and MT5), suggesting still alternative RpoS (and likely 
cAMP/CRP) independent evolutionary routes towards HHP resistance development exist. Nevertheless, these 
mutants might still have acquired mutations that directly affect the same downstream effector genes that are oth-
erwise governed by RpoS upregulation or cAMP/CRP downregulation.
In summary, this study (i) highlights attenuation of cAMP/CRP regulation as a novel and valid evolution-
ary route and an RpoS independent mechanism towards HHP resistance development in E. coli, and (ii) draws 
attention to the decreased fosfomycin susceptibility that tends to coincide with this route of HHP resistance 
development.
Strain MIC (mg/l)
WT 64
Δcrp 1,024
ΔcyaA 1,024
ΔrpoS 64
ΔrpoS Δcrp 1,024
ΔrpoS ΔcyaA 1,024
MT1 256
MT2 64
MT3 64
MT4 1,024
MT5 64
LMM1010 256
LMM1020 128
LMM1030 64
DVL20 64
DVL1 128
Table 2. Fosfomycin MICs obtained for E. coli MG1655 WT and its indicated mutants.
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Methods
Bacterial strains and growth conditions. E. coli K-12 MG165544 and its derivatives listed in 
Supplementary Table S1 were used throughout this study. The ∆rpoS knock-out of MG1655 was constructed by 
transferring the kanamycin resistance cassette replacing the rpoS locus of E. coli JW543745 by P1-transduction46. 
Further deletions of rssB, crp and cyaA loci were performed according to the method of Datsenko and Wanner47, 
using the cells of interest equipped with the plasmid pKD46 (encoding λ red recombinase genes behind the ara-
BAD promoter) and an amplicon prepared on pKD13 (containing the kanamycin resistance cassette) using the 
primers listed in Baba et al.45. The antibiotic marker was flanked by FRT sites to be further excised by transiently 
equipping the strain with the plasmid pCP20 (expressing the Flp site-specific recombinase48), resulting in the 
desired deletion mutant.
The crp alleles were reconstructed by the dual counter-selection system described by Li et al.49. Firstly, the 
crp gene was replaced by an amplicon containing the tetA-sacB marker prepared on E. coli XTL298 using the 
primers: 5 ′- CT AC CA GG TA AC GC GC CA CT CC GA CG GG AT TA AC GA GT GC CG TA AA CG AC AT CAAAGGG 
AAAACTGTCCATATGC-3 ′  and 5 ′-GGCGTTATCTGGCTCTGGAGAAAGCTTATAACAGAGG 
ATAACCGCGCATGTCCTAATTTTTGTTGACACTCTATC-3′. In a second step, counter-selection 
was used to replace the tetA-sacB cassette with a crp amplicon obtained by the following primers: 
5′-ACCCACTTCACTCGCGCTT-3′ and 5′-GGAACGAGGGAGAAGAGCAG-3′. Constructs were verified by 
PCR and sequencing using the locus specific primers described below.
Where indicated, the strains were transformed with pACYC184-crp (encoding the E. coli ATCC 43888 crp 
gene under the control of its native promoter18), pACYC184-cyaA (encoding the E. coli ATCC 43888 cyaA gene 
under the control of its native promoter18) or the corresponding backbone control plasmid (pACYC18450) by elec-
troporation. Please note that while crp and cyaA sequences originated from E. coli ATCC 43888, their sequence 
identities with the corresponding sequences of E. coli MG1655 are 99.5% and 98.2%, respectively, and both 
pACYC184-crp and pACYC184-cyaA proved to specifically attenuate the HHP resistance of ∆crp and ∆cyaA 
strains, respectively, in both wild-type (WT) and ∆rpoS backgrounds (Supplementary Fig. S3).
For strain construction, Lysogeny Broth (LB) medium51 was used and when necessary, a final concentration of 
50 μg/ml of kanamycin (Panreac-AppliChem, Darmstadt, Germany), 20 μg/ml of tetracycline (Sigma-Aldrich, St. 
Louis, MO, USA), 100 μg/ml of ampicillin (Fischer Scientific, Pittsburgh, PA, USA) or 30 μg/ml of chloramphen-
icol (Sigma-Aldrich) was added to select for the presence of recombined amplicons47, 49, pKD46 and pCP2047, 48  
or pACYC184-based vectors18, 50, respectively. For inactivation experiments, stationary phase cultures were 
obtained by inoculating test tubes containing 4 ml of Tryptone Soy Broth (TSB; Oxoid, Basingstoke, UK) with a 
single colony of the required strain prior to incubating the culture aerobically with shaking (300 rpm) for 18 h at 
37 °C. In pACYC184-based complementation assays, 30 μg/ml of chloramphenicol supplemented TSB was used 
to select for the presence of the plasmids18, 50.
HHP and heat treatment. Cells from a stationary phase culture, containing ca. 2 × 109 Colony Forming 
Units per milliliter (CFU/ml), were harvested by centrifugation (4000 × g, 5 min) and resuspended in an equal 
volume of 0.85% KCl (Sigma-Aldrich). For HHP treatment, 200 μl of the suspension was heat sealed in a sterile 
polyethylene bag after exclusion of the air bubbles and subjected to pressure (200–800 MPa) for 15 min in an 
8-ml pressure vessel (HPIU-10000, 95/1994; Resato, Roden, The Netherlands), held at 20 °C with an external 
water jacket connected to a cryostat. Both the slow pressure increase (100 MPa/min) and the external water jacket 
attenuated adiabatic heating during pressure build-up. Finally, decompression was almost instantaneous. For heat 
treatment, on the other hand, three sterile PCR tubes were aseptically filled with a 75 μl portion of resuspended 
cells and subjected to 57.0 °C for 15 min using a PCR apparatus (Tpersonal 48, Biometra GmbH, Goettingen, 
Germany). The intensity of HHP and heat treatment was chosen to inactivate ≥ 5 log10 reductions of the WT 
(800 MPa) or ∆rpoS (500 MPa; 57 °C) parental strain for a 15 min treatment in order to clearly observe levels of 
HHP and heat resistance development in the mutants and plasmid complementation effects. After HHP or heat 
treatment, samples were aseptically retrieved from the polyethylene bags or PCR tubes, respectively, and survival 
was determined as described below.
Selection of HHP-resistant mutants by directed evolution. To obtain E. coli MG1655 ΔrpoS mutants 
with enhanced pressure resistance, five independent cultures of this strain were reiteratively exposed to HHP 
shocks (15 min), progressively increasing pressure by 30 MPa each cycle (from 200 MPa to 470 MPa). After each 
HHP shock, an aliquot of the treated sample was inoculated 1/100 into fresh, prewarmed TSB and regrown for 
23 h at 37 °C prior to the next round of pressurization. After ten cycles of selection, two surviving clones from 
each of the evolved cultures were purified on TSA and rechallenged to the last HHP treatment (470 MPa) in order 
to select a clone that represented the HHP resistance of the evolved culture. Simultaneously, in order to determine 
the effect of the serial passage itself in the selection of E. coli HHP resistance, three independent lineages of the 
parental ΔrpoS strain were daily subcultured in the absence of HHP stress, which corresponded to ca. 6.6 ( = log2 
100) generations per day.
Determination of viability. Samples were serially diluted in 0.85% KCl supplemented with 0.1% bacteri-
ological peptone water (Oxoid), and subsequently 5 μl-samples of each dilution were spotted onto Tryptone Soy 
Agar (TSA; Oxoid), as previously described52. After 24 h of incubation at 37 °C, spots containing between 5–50 
colonies were counted, so that the quantification limit was 1,000 CFU/ml. The logarithmic reduction factor was 
calculated as log10 (N0/N), in which N0 and N represent the number of survivors in CFU/ml prior and after treat-
ment, respectively.
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Evaluation of cAMP/CRP downregulation in E. coli mutants. The functionality of cAMP/CRP reg-
ulation in E. coli mutants was screened indirectly by their ability to ferment lactose in MacConkey agar No 3 
(Lab M, Lancashire, UK). A spot of 20 µl of stationary phase cultures diluted 1/100 in 0.85% KCl was plated 
on the MacConkey agar supplemented with or without 5 mM of 3′,5′-cyclic adenosine monophosphate (cAMP; 
Calbiochem, Darmstadt, Germany), and then incubated overnight at 37 °C. E. coli forms pink colonies and a hazy 
precipitate of bile salts because of acidification53. Strains lacking crp or cyaA locus, and therefore compromised 
in lactose fermentation, form yellowish colonies because of ammonia production19. The addition of exogenous 
cAMP to MacConkey agar reverts the phenotype of ΔcyaA strains to the WT strain (Table 1).
To determine the ability of growth on glucose or lactose as the sole carbon source, stationary phase cultures 
were washed twice and diluted 1/100 in M9 salts51. Subsequently, 5 μl of this suspension was spotted on M9 agar 
supplemented with either D-glucose (0.4%; Sigma-Aldrich) or D-lactose (0.4%; Acros Organics, Morris Plains, 
NJ, USA) and incubated at 37 °C for 48 h.
The β-galactosidase assay was carried out as previously described by Miller51. Cells were grown in LB in the 
presence of 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG; Acros Organics) to mid-exponential phase. 
The β-galactosidase activity of permeabilized cells on ortho-nitrophenyl-β-galactoside (ONPG; Acros Organics) 
cleavage was measured in a Multiskan RC (Thermo Labsystems, Vantaa, Finland) and expressed in Miller units 
(MU).
Sequencing of rpoS, rssB, crp and cyaA loci of E. coli mutants. A PCR amplicon encompassing the 
open reading frame and its upstream promoter region of the E. coli MG1655 rpoS, rssB, crp and cyaA loci was 
generated using the site-specific primers previously described15, 18 and sequenced by Macrogen (Amsterdam, The 
Netherlands). The sequences were compared with those from the parental strain (WT or ∆rpoS background), 
which did not differ from the published genome of E. coli str. K-12 substr. MG1655 in the GenBank database44.
Fosfomycin susceptibility test. The minimal inhibitory concentration (MIC) for fosfomycin was 
determined by the broth microdilution method described by Jorgensen and Ferraro54. Serial twofold dilutions 
(1–4,096 mg/l) of fosfomycin (Sigma-Aldrich) in TSB were prepared in a 96-well plate and inoculated with 
5 × 105 CFU/ml of the corresponding E. coli mutant. The inoculated plate was incubated at 37 °C overnight. The 
MIC of fosfomycin was defined as the lowest concentration that inhibited visible growth of the corresponding 
mutant. MIC value for each strain was obtained in triplicate.
Statistical analysis. Statistical analyses, ANOVA and t-test, were carried out using the software GraphPad 
PRISM 5.0 (GraphPad Software Inc., San Diego, CA, USA), and differences were regarded as significant when P 
was ≤ 0.05. All microbial inactivation outcomes shown in figures correspond to averages and standard deviations 
calculated from three replicates performed in different working days. Miller units data correspond to averages 
and standard deviations obtained in three independent measurements.
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